(Q39849906)

15 September 2017

title

Expression of urokinase plasminogen activator and its receptor in advanced epithelial ovarian cancer patients (English)

1 reference

15 September 2017

1 reference

1 reference

Li Wang

1

1 reference

15 September 2017

Michele C Madigan

2

1 reference

15 September 2017

Hongmin Chen

3

1 reference

15 September 2017

Fenghua Liu

4

1 reference

15 September 2017

Kate I Patterson

5

1 reference

15 September 2017

Julia Beretov

6

1 reference

15 September 2017

Philippa M O'Brien

7

1 reference

15 September 2017

Yong Li

8

1 reference

15 September 2017

language of work or name

English

0 references

publication date

17 May 2009

1 reference

15 September 2017

1 reference

15 September 2017

volume

114

1 reference

15 September 2017

issue

2

1 reference

15 September 2017

page(s)

265-272

1 reference

Reproductive and dietary risk factors for epithelial ovarian cancer in China

15 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.04.031

Diagnosis and management of epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.04.031

Ovarian cancer metastasis: integrating insights from disparate model organisms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.04.031

The urokinase plasminogen activator system: role in malignancy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.04.031

Human breast cancer cell-mediated bone collagen degradation requires plasminogen activation and matrix metalloproteinase activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.04.031

The urokinase plasminogen activator system in cancer: recent advances and implication for prognosis and therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.04.031

Plasminogen activators and plasminogen activator inhibitors in blood and tumour fluids of patients with ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.04.031

Expression of urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in benign, borderline, malignant primary and metastatic ovarian tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.04.031

Prognostic significance of urokinase (uPA) and its inhibitor PAI-1 for survival in advanced ovarian carcinoma stage FIGO IIIc

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.04.031

Dedifferentiation of serous ovarian cancer from cystic to solid tumors is associated with increased expression of mRNA for urokinase plasminogen activator (uPA), its receptor (uPAR) and its inhibitor (PAI-1)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.04.031

High tumor tissue concentration of urokinase plasminogen activator receptor is associated with good prognosis in patients with ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.04.031

Prognostic value of plasma soluble urokinase plasminogen activator receptor (suPAR) in Danish patients with recurrent epithelial ovarian cancer (REOC).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.04.031

Expression of cyclooxygenase-2 in association with clinicopathological prognostic factors and molecular markers in epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.04.031

Evaluation of urokinase plasminogen activator and its receptor in different grades of human prostate cancer☆

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.04.031

Antigen levels of urokinase plasminogen activator and its receptor at the tumor-host interface of colorectal adenocarcinomas are related to tumor aggressiveness

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.04.031

High tissue content of urokinase plasminogen activator (u-PA) is associated with high stromal expression of u-PA mRNA in poorly differentiated serous ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.04.031

The urokinase-type plasminogen activator system in cancer metastasis: a review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.04.031

A role for caveolin and the urokinase receptor in integrin-mediated adhesion and signaling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.04.031

The plasminogen activation system in tumor growth, invasion, and metastasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.04.031

uPAR-uPA-PAI-1 interactions and signaling: a vascular biologist's view

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.04.031

New insights into the role of extracellular matrix during tumor onset and progression.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.04.031

Urokinase directly activates matrix metalloproteinases-9: a potential role in glioblastoma invasion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.04.031

Interaction between cancer cells and stromal fibroblasts is required for activation of the uPAR-uPA-MMP-2 cascade in pancreatic cancer metastasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.04.031

Proinvasive properties of ovarian cancer ascites-derived membrane vesicles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.04.031

New functions for the matrix metalloproteinases in cancer progression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.04.031

The clinical relevance of stromal matrix metalloproteinase expression in ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.04.031

Role of immunohistochemical overexpression of matrix metalloproteinases MMP-2 and MMP-11 in the prognosis of death by ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.04.031

Prognostic significance of stromal metalloproteinase-2 in ovarian adenocarcinoma and its relation to carcinoma progression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.04.031

Prominent expression of metalloproteinases in early stages of ovarian tumorigenesis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.04.031

Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.04.031

Matrix metalloproteinase inhibitors (MMPIs): the beginning of phase I or the termination of phase III clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.04.031

Matrix metalloproteinase inhibition of pancreatic cancer: matching mechanism of action to clinical trial design

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.04.031

Anti-cancer therapies targeting the tumor stroma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.04.031

Cytotoxicity of PAI2, C595 and Herceptin vectors labeled with the alpha-emitting radioisotope Bismuth-213 for ovarian cancer cell monolayers and clusters

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.04.031

A6, a urokinase plasminogen activator (uPA)-derived peptide in patients with advanced gynecologic cancer: a phase I trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.04.031

10.1016/J.YGYNO.2009.04.031

7 January 2021

Identifiers

DOI

1 reference

15 September 2017

1 reference